Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences has reported strategic and clinical updates for engineered IgM antibody programs, with a recent focus on autoimmune and inflammatory diseases. Company developments have included pipeline pivots, discontinuation of imvotamab and IGM-2644, restructuring actions, workforce reductions, governance changes, quarterly operating results, capital resources, and investor conference presentations.
Updates have also addressed bispecific T cell engager candidates, including imvotamab as a CD20 x CD3 program and IGM-2644 as a CD38 x CD3 program, as well as clinical disclosures in autoimmune indications such as rheumatoid arthritis and systemic lupus erythematosus.
IGM Biosciences (Nasdaq: IGMS) announced significant advancements, including FDA clearance for its IND application for IGM-8444, aimed at treating solid and hematologic malignancies. The Phase 1 trial will assess its efficacy alongside chemotherapy. Additionally, Kathy Miller, Ph.D., has been appointed Vice President of Antibody Discovery. Financially, IGM reported a Q2 2020 net loss of $18.8 million, an increase from the previous year, with cash reserves decreasing to $203.1 million. The company's guidance for 2020 remains unchanged, anticipating $75-$85 million in non-GAAP operating expenses.
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology firm specializing in engineered IgM antibodies, announced that CEO Fred Schwarzer will present at the Jefferies 2020 Healthcare Conference. The presentation is scheduled for Thursday, June 4, at 10:00 a.m. ET, and will be conducted virtually. Interested participants can access a live webcast through the company’s website, with a replay available for 90 days post-event. IGM Biosciences focuses on advancing IgM antibody technologies, addressing existing manufacturing challenges since its inception in 2010.
IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology firm in Mountain View, California, focuses on engineered IgM antibodies. On May 12, 2020, the company announced that CEO Fred Schwarzer will present at the 2020 RBC Capital Markets Global Healthcare Conference on May 19 at 4:15 p.m. ET. The event will be virtual, and a live webcast can be accessed from the Company’s website, with a replay available for 90 days after the event.
IGM Biosciences has developed a proprietary IgM technology platform, aimed at enhancing the therapeutic applications of IgM antibodies.
IGM Biosciences (Nasdaq: IGMS) reported its Q1 2020 financial results, revealing a net loss of $17.6 million or $0.58 per share, compared to a loss of $7.5 million or $16.86 per share in Q1 2019. R&D expenses surged to $14.6 million from $5.9 million a year earlier. The company has $219 million in cash and investments as of March 31, 2020. Key developments include a collaboration with Atreca and BeiGene for COVID-19 antibody treatment, and upcoming IND filings for IGM-8444 and IGM-7354. Initial data from IGM-2323 Phase 1 trial is expected in H2 2020.